95 related articles for article (PubMed ID: 2444507)
1. Serum lysozyme activity in patients with Hodgkin's disease undergoing chemotherapy.
Prokopowicz J; Kemona H; Wysocka J; Kiluk S
Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(3):338-47. PubMed ID: 2444507
[TBL] [Abstract][Full Text] [Related]
2. Serum lysozyme activity in patients with lung carcinoma subjected to radiotherapy.
Prokopowicz J; Kemona H; Wysocka J; Kiluk S
Neoplasma; 1985; 32(5):605-11. PubMed ID: 4069293
[TBL] [Abstract][Full Text] [Related]
3. Plasma and leukocytic bactericidal activity in the course of chemotherapy of Hodgkin's disease.
Wysocka J; Kemona H; Prokopowicz J; Kiluk S
Acta Med Pol; 1987; 28(1-4):99-107. PubMed ID: 3506375
[No Abstract] [Full Text] [Related]
4. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
5. Mopp chemotherapy in the treatment of stage IV Hodgkin's disease.
Fiacchini M; Lauria F; Mazza P; Cantore M; Gherlinzoni F; Tura S
Haematologica; 1985; 70(2):148-54. PubMed ID: 3924778
[No Abstract] [Full Text] [Related]
6. Genetic instability in patients with Hodgkin's disease undergoing chemotherapy.
Abdallah JM; Lombardi DP; Kirsch IR
J Clin Invest; 1995 Dec; 96(6):2744-7. PubMed ID: 8675643
[TBL] [Abstract][Full Text] [Related]
7. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
8. [A trial of applying an oily suspension of bleomycin endolymphatically in patients with Hodgkin's disease of the extraperitoneal lymph nodes].
Ziółko E
Pol Merkur Lekarski; 1997 Jul; 3(13):8-9. PubMed ID: 9432303
[TBL] [Abstract][Full Text] [Related]
9. The role of dose and rate of administration of MOPP drugs in 97 retrospective Hodgkin's patients.
Gobbi PG; Cavalli C; Rossi A; Bertoloni D; Galeone F; Pieresca C; Grignani E
Haematologica; 1987; 72(6):523-8. PubMed ID: 3126109
[No Abstract] [Full Text] [Related]
10. [Second tumors in patients treated for Hodgkin's disease].
España P; Bonilla F; Yebra M; Diego J; Alvarez de Mon M; Marazuela M; Durántez A
Rev Clin Esp; 1988 Apr; 182(6):304-6. PubMed ID: 3406475
[No Abstract] [Full Text] [Related]
11. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
12. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of Hodgkin's disease including the staging laparotomy].
Yosida T; Nakanisi J; Kobayasi S; Ohtake S; Ito K; Nakamura S; Hattori K; Saito Y; Tanimoto K
Rinsho Ketsueki; 1984 Jun; 25(6):827-34. PubMed ID: 6548266
[No Abstract] [Full Text] [Related]
14. [Hodgkin's disease. Study of 100 cases].
Sans-Sabrafen J; Pedro Olivé C; Buxó Costa J; Pardo Peret P; Rodríguez Ferrera JC; Woessner S; Galofré M; Rodríguez Méndez F
Med Clin (Barc); 1987 Feb; 88(5):175-8. PubMed ID: 3561046
[No Abstract] [Full Text] [Related]
15. [Clinical features and treatment of Hodgkin's disease].
Shirakawa S; Kita K; Kobayashi T; Ohno T
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):421-34. PubMed ID: 3754108
[TBL] [Abstract][Full Text] [Related]
16. [CVP or C-MOPP combination chemotherapy in the treatment of advanced Hodgkin's disease and non-Hodgkin's lymphoma (intermediate grade of working formulation)].
Sampi K; Honda T; Hattori M
Rinsho Ketsueki; 1984 Feb; 25(2):164-8. PubMed ID: 6547984
[No Abstract] [Full Text] [Related]
17. [MOPP therapy of Hodgkin's disease previously treated with MOPP].
Frau A; Montalar J
Med Clin (Barc); 1985 May; 84(19):801. PubMed ID: 3839875
[No Abstract] [Full Text] [Related]
18. [Chemotherapy of stage III-IV Hodgkin's disease. A retrospective analysis of the 53 cases collected from 9 institutions in Japan].
Takagi T; Ohnoshi T; Hayashi K; Ohtake S; Sampi K; Sawada U; Kuraishi Y; Kondo M; Suzuki H; Oyama A
Rinsho Ketsueki; 1989 Jul; 30(7):994-8. PubMed ID: 2681883
[TBL] [Abstract][Full Text] [Related]
19. Comparison of MOPP/MOPP +/- RT vs. MOPp/ABVD +/- RT in poor prognosis Hodgkin's disease. Long-term results.
Comella P; Abate G; Fiore M; Di Finizio G; Frezza P; Scoppa G; Anania C; Coucourde F; Zarrilli D
J Chemother; 1989 Jul; 1(4 Suppl):1254-6. PubMed ID: 16312855
[No Abstract] [Full Text] [Related]
20. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure.
Campbell B; Wirth A; Milner A; Di Iulio J; MacManus M; Ryan G
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1538-45. PubMed ID: 16125872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
